drug_type
RELEVANT_DRUG
intervention_type
Targeted therapy (monoclonal antibody; anti-EGFR)
drug_description
Anti-EGFR monoclonal antibody that blocks EGFR signaling (effective in RAS/RAF wild-type tumors).
nci_thesaurus_concept_id
C1723
nci_thesaurus_preferred_term
Cetuximab
nci_thesaurus_definition
A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors.
drug_mesh_term
Cetuximab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Cetuximab is a chimeric anti-EGFR monoclonal antibody that binds the extracellular domain of EGFR, blocks ligand binding and receptor dimerization, thereby inhibiting downstream MAPK/PI3K signaling to suppress tumor cell proliferation and survival; efficacy is seen in RAS/RAF wild-type tumors and it may also mediate ADCC via its Fc region.
drug_name
Cetuximab
nct_id_drug_ref
NCT06525428